Ovarian Stimulation in IVF: Is More Medication Always the Better Bet?

Ovarian stimulation in IVF aims to obtain usable eggs while managing treatment burden and risks such as OHSS. More retrieved eggs and a higher prescribed hormone dose are not interchangeable measures. Individualized dosing considers ovarian reserve, prior response and safety rather than assuming that more medication must improve outcomes.

Egg numbers matter because each retrieved egg represents a possible opportunity. That does not mean that raising the medication dose always produces more usable embryos or improves cumulative live birth.

The question is how to balance expected response, safety and burden for the individual patient.

The Paradigm Shift: From Maximum Harvest to Precision Stimulation

Recent guidelines from the European Society of Human Reproduction and Embryology (ESHRE) reflect a significant departure from past practices. Rather than aiming for a maximum “catch,” the focus has shifted toward tailored, patient-specific protocols.

Clinicians are now prioritizing a “precision-first” approach that integrates:

Ovarian Reserve Biomarkers: AMH levels and Antral Follicle Counts (AFC).
Personal Physiology: BMI, age, and historical responses to previous cycles.
Prior response: More medication may add burden without overcoming limited response.

Dose and yield are different questions

An association between more retrieved eggs and cumulative success cannot prove that a higher prescribed FSH dose improves outcomes. Patient selection and ovarian response affect both.

This biological reality is shifting the conversation in the consultation room. Doctors are moving away from the question, “How many eggs did we get?” and moving toward, “How many of these are developmentally competent embryos?”

A biological system with limits

Stimulation recruits responsive follicles; it cannot create new ovarian reserve. A treatment plan should account for:

Safety: Expected response and OHSS risk.
Burden: Medication, monitoring and cost.
Outcomes: Usable embryos and cumulative live birth, not dose alone.

The Era of Precision Medicine

The new era of IVF is defined by a delicate balance: the “Goldilocks Zone” of stimulation. The goal is no longer to push the ovaries to their absolute limit, but to find the optimal point of stimulation that produces a high-quality cohort of embryos without compromising the patient’s internal environment.

Clinical judgment combines evidence, response monitoring and patient priorities. No dosing formula can guarantee the quality of a particular egg.

The goal is a useful, safe response

Individualization avoids treating maximum dose as a goal in itself while recognizing that egg quantity still has clinical relevance.

Disclaimer: This content is provided for informational purposes, based on recent advancements in reproductive medicine. Medical judgments and treatment decisions must always be made in consultation with professional medical personnel. Image: AI-generated (ChatGPT, OpenAI) / Visual reference for illustrative purposes only.

Dose decisions need an individual context

Expected response, safety and outcomes should guide stimulation rather than maximum medication alone. ESHRE ovarian stimulation guideline (2025 update).